Pharmafile Logo
Pharmafocus logo
Advanced Search

horizon

Showing 11 posts of 11 posts found.

shutterstock_123182704

Horizon and Fulcrum Therapeutics form CRISPR collaboration

September 6, 2016
Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …

News
money_pills_2

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

May 20, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …

News
money_pills_2

Depomed criticised by investors and urged to explore potential sale

April 11, 2016
Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value

Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …

News
EU flags

Horizon receives European go-ahead for Ravicti

December 2, 2015
Research and Development, Sales and Marketing Horizon Pharma, Ravicti, horizon, orphan drug, rare disease, urea cycle disorders

The European Commission has approved Ravicti for rare urea cycle disorders.  Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon …

News
Nucynta (tapentadol)

Takeover hostilities resume between Depomed and Horizon

August 10, 2015
Sales and Marketing Depomed, horizon, hostile bid, nucynta, takeover, tapentadol

The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it …

News
depomedlogo

Depomed rejects Horizon’s latest takeover bid

July 30, 2015
Sales and Marketing Depomed, horizon, mergers and acquisitions, takeovers

Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company. The Irish pharma company …

News
Deopmed logo

Horizon attempts a hostile $3bn Depomed takeover

July 9, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, M&A, MA, acquisitions, horizon, mergers, takeover

Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion. Horizon, a biopharma company focussed …

News
Astrazeneca image

AZ and Horizon in cancer tie-up

January 8, 2014
Research and Development, Sales and Marketing AstraZeneca, Cancer, horizon, medimunne

 AstraZeneca has signed a deal with British biotech firm Horizon Discovery to look at a number of genotypes to see …

News
Vimovo image

AstraZeneca sells arthritis drug for $35 million

November 20, 2013
Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo

AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million.  AZ retains …

News
dav

Horizon Discovery chairman steps down from Board

October 24, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing evans, horizon

Research tools firm Horizon Discovery has confirmed that David Evans has stepped down as chairman of its Board. Dr Ian …

Appointment

Boehringer in oncology tie-up

January 16, 2013
Research and Development, Sales and Marketing Boehringer, Cancer, horizon, x-man

Boehringer Ingelheim has entered a five-year tie-up with a UK biotech company which specialises in helping research into personalised medicines. …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024